Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland (HepCOP)

This study has been completed.
University of Zurich
Information provided by:
Seidenberg, Arztpraxis A., M.D.
ClinicalTrials.gov Identifier:
First received: May 15, 2007
Last updated: February 13, 2009
Last verified: May 2007

Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.

Hepatitis C, Chronic
Substance Abuse Treatment Centers
Opioid-Related Disorders

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung

Resource links provided by NLM:

Further study details as provided by Seidenberg, Arztpraxis A., M.D.:

Study Start Date: July 2007
Study Completion Date: December 2007
Detailed Description:

Genders Eligible for Study:   Both
Study Population
Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland

Inclusion Criteria:

  • Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00473993

Sponsors and Collaborators
Seidenberg, Arztpraxis A., M.D.
University of Zurich
Study Director: André Seidenberg, Dr.med. research fellow EHAM, University of Zurich
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00473993     History of Changes
Other Study ID Numbers: HepCOP Zurich 
Study First Received: May 15, 2007
Last Updated: February 13, 2009
Health Authority: Switzerland: Ethikkommission

Keywords provided by Seidenberg, Arztpraxis A., M.D.:
Hepatitis C
Opioid Maintenance Treatment
Interferon, pegylated

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Opioid-Related Disorders
Chemically-Induced Disorders
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Mental Disorders
Picornaviridae Infections
RNA Virus Infections
Substance-Related Disorders
Virus Diseases

ClinicalTrials.gov processed this record on April 27, 2016